Table 3.
Basal and UVA-stimulated horny layer MDA content
| Basal level | 0 | 0.5 M | 1 M | 2 M | ||||
|---|---|---|---|---|---|---|---|---|
| 100 mg | 2.61±0.13 | 2.17±0.09*** (−14.4%) | 2.01±0.07*** (−18.5%) | 1.98±0.05*** (−18.7%) | ||||
| 250 mg | 2.72±0.16 | 1.94±0.12*** (−25.5%) | 1.60±0.08*** (−37.7%) | 1.69±0.07*** (−32.6%) | ||||
| Placebo | 2.58±0.10 | 2.60±0.11 (+1.3%) | 2.50±0.09 (−1.2%) | 2.47±0.09 (−2.3%) | ||||
| UVA stimulated | 0 | 0.5 M | 1 M | 2 M | ||||
| 4 h | 24 h | 4 h | 24 h | 4 h | 24 h | 4 h | 24 h | |
| 100 mg | 40.8% | 25.6% | 31.1%** | 16.9%*** | 24.6%*** | 12.2%*** | 20.7%*** | 10.5%*** |
| 250 mg | 37.5% | 24.0% | 27.3%*** | 14.9%*** | 21.1%*** | 10.7%*** | 15.8%*** | 8.2%*** |
| Placebo | 39.7% | 26.3% | 44.7%*** | 30.8%*** | 45.1%*** | 30.7%*** | 49.0%*** | 30.1%*** |
Data are means (µM MDA)±SE. Values in brackets: % variation vs. 0.
*
p < 0.05
**
p < 0.01
***
p < 0.001.
UVA stimulated LPOs are % variation vs. baseline.